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Background: Recurrent gynecologic cancers are often difficult to manage without signif-
icant morbidity. We conducted a phase II study to assess the safety and the efficacy of
ablative robotic stereotactic body radiosurgery (SBRT) in women with metastatic gyne-
cologic cancers. Methods: A total of 50 patients with recurrent gynecologic cancer who
had single or multiple (≤4) metastases underwent robotic-armed Cyberknife SBRT (24Gy/3
daily doses). Toxicities were graded prospectively by common toxicity criteria for adverse
events (version 4.0). SBRT target responses were recorded following RECIST criteria (ver-
sion 1.0). Rates of clinical benefit for SBRT and non-radiosurgical disease relapse were
calculated. Disease-free and overall survivals were estimated by the Kaplan–Meier method
and the Cox proportional hazards model was used to control for prognostic variables. Find-
ings: SBRT was safely delivered, with 49 (98%) of 50 patients completing three prescribed
fractions.The most frequent grade 2 or higher adverse events attributed to SBRT included
fatigue (16%), nausea (8%), and diarrhea (4%). One (2%) grade four hyperbilirubinemia
occurred. SBRT target response was 96% (48 of 50 patients). A 6-month clinical benefit was
recorded in 34 [68% (95% CI, 53.2, 80.1)] patients. No SBRT targeted disease progressed.
Non-radiosurgical disease relapse occurred in 31 (62%) patients. Median disease-free sur-
vival was 7.8 months (95% CI, 4.0, 11.6). Median overall survival was 20.2 months (95% CI,
10.9, 29.5). Interpretation: SBRT safely controlled metastatic gynecologic cancer targets.
Given an observed high rate of non-radiosurgical disease relapse, a phase I trial assess-
ing co-administration of SBRT and cytotoxic chemotherapy is underway. Funding: Case
Comprehensive Cancer Center.
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INTRODUCTION
Leading causes of cancer-related death in women worldwide
include metastatic and recurrent ovarian, uterine, uterine cervix,
and vulvar cancers (Ferlay et al., 2010). When these cancers
metastasize after primary surgical, chemotherapy, or radiother-
apy, conventional treatment options often are associated with
morbidity. These women therefore have an unmet therapeutic
need. As many as 40% of women with gynecologic cancer have
disease relapse occurring in previously irradiated tissues or occur-
ring near chemotherapy-taxed bone marrow (Kunos et al., 2012a).
Because of prior surgical, chemotherapy, and radiation treatment,
it is often difficult to use radiotherapy without functional haz-
ard to normal organs. Extracranial stereotactic body radiosurgery
(SBRT) permits a non-invasive therapeutic option for women with
gynecologic cancer disease relapse.
Stereotactic body radiosurgery offers advantages, when com-
pared to other radiation therapy platforms, both in its accounting
of target motion and in its eloquent dosimetry. Indeed, SBRT
capitalizes upon on-board image guidance of “pencil beam-sized”
portals delivering hypofractionated radiation (Kunos et al., 2008,
2009, 2011, 2012a; Choi et al., 2009; Deodato et al., 2011; Higgin-
son et al., 2011). Except for recognized normal organ tolerances
to ablative radiation dose, (Timmerman, 2008) patient eligibil-
ity guidelines for SBRT remain controversial in the management
of gynecologic cancers. As one example of a SBRT platform, the
Cyberknife®system [Accuray (Sunnyvale, CA, USA)] utilizes a lin-
ear accelerator mounted to an industrial robotic arm to direct
radiation dose, without the use of a rigid frame, precisely at
cancer targets while tracking cancer-target motion during the
treatment, ultimately achieving submillimeter accuracy (Wilcox
and Daskalov, 2007).
This phase II clinical trial was designed to evaluate whether
ablative radiation could control metastatic gynecologic cancer
with acceptable toxicity levels. Institutional experiences of SBRT
alone in patients with gynecologic cancers have shown SBRT
to have modest toxicity, (Kunos et al., 2008, 2009, 2012a; Choi
et al., 2009; Deodato et al., 2011; Higginson et al., 2011) with
radiation dose and number of radiosurgical fractions important
determinants of side effects (Timmerman, 2008). As such, we
investigated the safety and efficacy of ablative robotic SBRT in this
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first-reported clinical trial conducted in women with metastatic
gynecologic cancers.
METHODS
STUDY DESIGN AND PATIENTS
For this clinical trial, patients were included if they were women
18 years of age or older. Patients had an Eastern Cooperative Group
performance status of 0, 1, 2, or 3. Patients must have had a single
metastasis or metastases (≤4) of a pathologically confirmed gyne-
cologic cancer whose dimensions could be measured by RECIST
criteria (version 1.0; Nishino et al., 2010). In this trial, there was
no constraint for the total planned radiosurgical target volume.
Patients may not have had cryosurgery or radiofrequency ablation
in the planned radiosurgical target (as these forms of treatment
would obscure SBRT response measurements). Patients must have
had adequate pretherapy hematological and renal function. There
were no pretherapy limits for the number of prior chemotherapy
cycles or radiation dosage. Patients must have stopped anticancer
therapies for 4 weeks before SBRT.
Fifty women met these criteria between July 2009, and Septem-
ber 2011. Their demographics, gynecologic cancer type, number
of SBRT target metastases, and prior chemotherapies or radiation
are cataloged in Table 1. All patients provided written informed
consent. University Hospitals of Cleveland and Case Western
Reserve University (Cleveland, OH, USA) Institutional Review
Board approval was granted for this clinical trial. Oversight for the
data and safety monitoring plan was provided by the Case Com-
prehensive Cancer Center of University Hospitals of Cleveland and
Case Western Reserve University.
STEREOTACTIC BODY RADIOSURGERY
For radiosurgical planning, patients underwent same-day
thorax to mid-thigh non-contrasted contiguous axial com-
puted tomography (CT) high-resolution imaging (voxel
0.98 mm× 0.98 mm× 1 mm, technique: 120 kVp, 450 mAs) and
axial 18F-deoxyglucose positron emission tomography (18F-FDG
PET) images acquired in the head-first supine position (voxel:
4 mm× 4 mm× 4 mm) following institutional protocol, (Kunos
et al., 2011, 2012a) CT and 18F-FDG PET images were imported,
digitally overlaid, and co-registered for inverse radiation treat-
ment planning on the MultiPlan 3.5.2 Treatment Planning Sys-
tem (Accuray). Based on these images, we targeted their entire
known disease burden as a clinical target volume (CTV) because
it included delineated gross tumor volume (GTV) and 18F-FDG
PET signal outside the GTV. A 3.0 mm margin was added to the
CTV for a planning tumor volume (PTV). Normal tissue contours
were applied. The radiation prescription was three daily fractions
of 8 Gy per fraction totaling 24 Gy (typically prescribed to the 70%
isodose line). Fixed tungsten circular collimators (5–60 mm) or a
tungsten-copper alloy iris aperture collimated a 6 MV radiation
beam. For additional details, the reader is referred to a peer-
reviewed, video-complemented algorithm for the three outpatient
robotic SBRT treatment sessions (Kunos et al., 2012b).
SAFETY ASSESSMENTS
Patients underwent physical examination, hematologic, and renal
blood tests as well as baseline CT and 18F-FDG PET scans within
Table 1 | Baseline characteristics of the study patients.
Characteristic
Women – no. (%) 50 (100)
Age – year
Median 66
Range 27−82
Race – no. (%)*
White 41 (82)
Black or African ancestry 6 (12)
Hispanic 3 (6)
Ecog performance status – no. (%)
†
0 36 (72)
1 7 (14)
2 7 (14)
3 0 (0)
No. of metastases to be treated by radiosurgery – no. (%)
1 14 (28)
2 21 (42)
3 13 (26)
4 2 (4)
≥4 0 (0)
Histopathology – no. (%)
Cervix/vagina squamous cell carcinoma 9 (18)
Endometrial adenocarcinoma 14 (28)
Ovarian adenocarcinoma 25 (50)
Vulvar squamous cell carcinoma 2 (4)
Prior radiation – no. (%) 22 (44)
Inclusive of radiosurgery site 16 (32)
>5000 cGy delivered pretherapy to radiosurgery site 13 (26)
Prior chemotherapy (any) – no. (%) 47 (94)
No. of prior courses of chemotherapy for metastates – no. (%)
0 28 (56)
1 20 (40)
2 2 (4)
Platinum-containing regimen – no. (%) 21 (42)
Taxane-containing regimen – no. (%) 14 (28)
Anthracycline-containing regimen – no. (%) 6 (12)
Topotecan-containing regimen – no. (%) 5 (10)
Gemcitabine-containing regimen – no. (%) 5 (10)
*Race was self-reported.
†The Eastern Cooperative Group (ECOG) performance status reflects individual
daily living activities on a scale of 0 (fully active with symptoms) to 5 (dead).
no.=number.
28 days before the first SBRT treatment. Physical examinations, CT
scans for response, and adverse event assessments [graded 0 (none)
to 5 (fatal), according to Common Toxicity Criteria for Adverse
Events (version 4.0)] were repeated at 1 and 3 months mandatorily.
Thereafter, these evaluations were recommended every 6 months,
with additional imaging and blood tests repeated at the option of
the treating physician.
EVALUATION OF CLINICAL ACTIVITY AND STATISTICAL METHODS
Stereotactic body radiosurgery target responses were recorded fol-
lowing RECIST (Nishino et al., 2010). A rate of clinical benefit
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for SBRT was calculated [i.e., number of complete (CR)+ partial
(PR)+ stable disease (SD) response for ≥6 months, without new
elsewhere progression of disease (PD)]. Local disease relapse
was defined as disease progression of the SBRT target(s). Non-
radiosurgical target (i.e., disease not targeted by SBRT on this clin-
ical trial, but amenable to subsequent treatment including SBRT)
distant disease relapse was scored as disease progression. Time at-
risk for disease progression or death was measured from the first
date of SBRT. Univariate product-limit estimates [95% confidence
interval (C.I.)] for progression-free (i.e., disease relapse and death)
and overall survival were calculated utilizing the method of Kaplan
and Meier (SPSS 18.0, Chicago, IL, USA; Kaplan and Meier, 1958).
Descriptive and graphical statistics were computed using statistical
software (SPSS 18.0). For this clinical trial, the number of enrollees
(n= 50) was selected arbitrarily.
RESULTS
PATIENTS
Between July 24, 2009 and September 7, 2011, 50 patients under-
went SBRT for metastatic gynecologic cancers. A total of 49
patients (98%) received all three prescribed SBRT treatments.
One patient did not complete her third fraction of SBRT due
to intractable back pain which prevented her from lying on the
treatment table. All 50 patients were included in the SBRT safety
analysis. As of the date of data cutoff (April 15, 2012), all patients
have completed SBRT and have been followed for 6 months or
more unless cancer-related death occurred. The median follow-
up for surviving patients was 15 months (range, 1–31 months).
Four (8%) patients received adjuvant chemotherapy before their
scheduled second confirmatory assessment of their disease status.
Patients with metastatic ovarian (50%), uterine (28%), uterine
cervix (18%), and vulvar (4%) cancers were enrolled on this clin-
ical trial (Table 1). Overall, 22 patients (44%) had received prior
radiation and 47 patients (94%) had received prior chemother-
apy for both initial therapies and recurrent disease before SBRT.
A total of 29 patients (58%) received SBRT treatment as first-line
therapy for metastatic gynecologic cancer disease. No patient had
received SBRT prior to clinical trial enrollment. SBRT sites of treat-
ment and its treatment parameters are listed in Table 2. SBRT was
used for lymph node sites of metastatic disease (including para-
aortic, pelvic, and groin nodes) in 34 of 50 patients (68%). The
median SBRT PTV that encompassed the entirety of known CT
and 18F-FDG PET identified targets was 68 cm3 (range: 4–613 cm3;
Table 2). An example of SBRT treatment is illustrated in Figure 1.
SAFETY
Table 3 lists all types (i.e., any early ≤30 day or late >30 day) and
frequencies of at least possibly SBRT-related adverse events among
all 50 patients. The most frequent adverse events were grade 1
or 2 fatigue (20%) and grade 1 or 2 nausea (12%). Fatigue and
nausea resolved spontaneously in all nine patients by the 30-day
posttherapy physician assessment. The incidence of grade 3 or
grade 4 possible SBRT-related non-hematological toxicities was
6%; these events included non-infectious diarrhea, enterovaginal
fistula, and hyperbilirubinemia. Grade 3 or grade 4 neutropenias,
thrombocytopenias, or anemias attributable to SBRT were not
observed within 30 days posttherapy. One death (2%) occurred
Table 2 | Stereotactic body radiosurgery sites of treatment and
treatment parameters.
TREATMENT SITE – NO. (%)
Para-aortic lymph nodes 19 (38%)
Pelvis lymph nodes/pelvis soft tissue site 14 (28%)
Upper abdomen (excluding para-aortic lymph
nodes, liver)
2 (4%)
Liver 8 (16%)
Lung 4 (8%)
Thoracolumbar spine 2 (4%)
Groin lymph nodes/perineal soft tissue site 1 (2%)
TREATMENT PARAMETERS
Median prescription dose (dose× fractions) 2400 cGy (800 cGy×3)
Median prescription isodose (25–75%
quartile)
70% (70−80%)
Radiosurgical tracking
By gold seed fiducials – no. (%) 44 (88%)
By bony spine landmarks – no. (%) 6 (12%)
Radiosurgical beam collimation
By fixed collimator – no. (%) 23 (46%)
By iris collimator – no. (%) 27 (54%)
Synchrony motion tracking – no. (%) 25 (50%)
Median planning tumor volume (25–75%
quartile)
68 cm3 (29 −124 cm3)
no.=number.
within 30 days of SBRT due to non-radiosurgical target disease
progression resulting in end-organ failure. Among 16 women who
had their SBRT treatment overlap their prior external beam radia-
tion therapy site, a single (6%) grade 3 diarrhea adverse event was
observed.
EFFICACY
The SBRT target response rate (target CR+ target PR) was 96%
(48 of 50 patients). A confirmed SBRT target CR, meaning disap-
pearance of all target and non-target lesions and no new evidence
of disease progression, occurred in a single patient [1 (2%) of 50
patients]. Two of the 50 patients (4%) had SBRT target stable dis-
ease; one of these patients with a treated lumbar vertebral body
metastasis died within 4 weeks of SBRT due to non-radiosurgical
lung and marrow disease progression. No local disease relapses
were recorded in SBRT targets. However, non-radiosurgical target
distant disease relapse occurred in 31 patients (62%). In these 31
patients, the most frequent new distant sites of disease were the
lungs [12 (39%)], abdomen, or pelvis [12 (39%)], liver [4 (13%)],
bone [2 (6%)], and inguinal lymph nodes [1 (3%)]. The medial
interval to distant disease relapse calculated from the first date of
SBRT was 5 months (range, 1–16 months). As such, and exclud-
ing the one patient with lumbar vertebral disease, the best overall
response rate by RECIST was 61% (30 of 49 patients). The rate
of clinical benefit (i.e., 6-month CR+PR+ SD without PD) was
68% (34 of 50 patients, 95% CI, 53%, 80%).
As of this writing, 24 patients (48%) have died. Eighty-three
percent of deaths (20 of 24) were attributable to non-radiosurgical
metastatic gynecologic cancer disease progression. The median
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FIGURE 1 | (A) Depicted are the 140 treatment beams by the Cyberknife
radiosurgery 6 MV accelerator for treatment during the targeting of left-sided
para-aortic lymph nodes. (B–D) Depicted are axial, coronal, and sagittal
projections of radiosurgical treatment. The 18F-FDG PET/CT-derived clinical
target volume (red shaded volume) and 3 mm expanded planning tumor
volume (green shaded volume) are contoured. The 24 Gy prescription isodose
is highlighted in red and a 10 Gy isodose is outlined in light blue. Contouring of
the bowel (magenta), liver (orange), right kidney (light blue), and left kidney
(dark blue) is shown. (E) Plotted are corresponding radiation dose-volume
histograms for clinical targets and organs at-risk.
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Table 3 | Stereotactic body radiosurgery-related worst grade toxicities.
Adverse event Grade
1 2 3 4
Cardiovascular
Lymphedema 0 1 0 0
Constitutional symptoms
Fatigue 2 8 0 0
Anemia 0 1 0 0
Gastrointestinal
Anorexia 1 1 0 0
Constipation 1 0 0 0
Diarrhea 1 1 1 0
Abdominal bloating 1 0 0 0
Gastritis 1 0 0 0
Nausea 2 4 0 0
Vomiting 0 1 0 0
Genitourinary
Urethra injury 0 1 0 0
Ureteral obstruction 0 1 0 0
Fistula – vagina 0 0 1 0
Infection
Febrile Neutropenia 0 0 0 0
Neutropenia 0 0 0 0
Metabolic/laboratory
Liver dysfunction – clinical 0 1 0 0
International normalized ratio (INR) of prothrombin time 1 0 0 0
Hyperbilirubinemia 0 0 0 1
Thrombocytopenia 0 0 0 0
Pain
Abdominopelvic pain 0 5 0 0
Chest Wall arthralgia/myalgia 3 0 0 0
Total 13 25 2 1
progression-free survival was 7.8 months (95% CI, 4.0, 11.6). The
median overall survival was 20.2 months (95% CI, 10.9, 29.5).
A total of 4 of 50 patients (8%) received adjuvant chemother-
apy before second confirmatory assessment of their disease status.
Patients given chemotherapy received a median of four cycles of
carboplatin-containing chemotherapy regimen. The combination
of SBRT and chemotherapy led to a progression-free survival of
8.1 months (95% CI, 3.4, 12.8). A statistical comparison of an
SBRT treatment alone and SBRT plus chemotherapy treatment
was not done due to small sample size in the latter cohort.
DISCUSSION
This phase II clinical trial showed that SBRT effectively controls
metastatic disease at a high rate with minimal toxicity in patients
with metastatic gynecologic cancers.
Contrary to the typical phase II efficacy end point of overall
rate of response, we chose the rate of clinical benefit as the pri-
mary end point. Clinical benefit (i.e., number of CR+PR+ SD
responses for≥6 months, without new elsewhere PD) was chosen
on the presumption that radiosurgery can only exert measurable
cytotoxic effects on targeted disease. Radiosurgery cannot be held
accountable to control disease undetected by CT and 18F-FDG
PET imaging. For this reason, objective responses (complete or
partial) or disease stabilization were regarded clinically meaning-
ful in assessing the antitumor activity of SBRT. Progression of
disease elsewhere in the body shortly after SBRT might signal (1)
progression of already-present occult disease, or (2) inability of
SBRT to control targeted disease prior to disease dissemination.
Stereotactic body radiosurgery has demonstrated activity
against gynecologic cancer at various ablative doses and schedules
(Kunos et al., 2008, 2009, 2012a; Choi et al., 2009; Deodato et al.,
2011; Higginson et al., 2011). In our study, 24 Gy divided into three
consecutive 8 Gy daily fractions were given to take radiobiological
advantage of relative radiosensitivity of gynecologic malignancies.
The SBRT target rate of response (96%) is in accord with rates
described in previous studies of SBRT for metastatic gynecologic
cancer (range, 67–79%; Kunos et al., 2008, 2009, 2012a; Choi et al.,
2009; Deodato et al., 2011; Higginson et al., 2011).
Our observation that 62% of patients eventually develop dis-
tant disease progression after undergoing SBRT attests to the need
of concurrent chemotherapy co-administration. Too few patients
received chemotherapy in close proximity to dose of SBRT to com-
ment on the safe co-administration of cytotoxic chemotherapies.
However, we do suggest cautiously that SBRT may contribute to a
lengthened progression-free survival. In some previously reported
studies, patients with metastatic ovarian, uterine, uterine cervix,
and vulvar cancers have a median progression-free survival of
3 months (range, 2–4 months) and overall survival of 9 months
(range, 6–15 months; Long et al., 2005; Dizon et al., 2009; Wit-
teveen et al., 2009; De Geest et al., 2010). In our very heterogeneous
patient population undergoing a variety of pretreatment radiation
and chemotherapy regimens, we observed a progression-free sur-
vival of 7.8 months and overall survival of 20.2 months. We do
not presume that SBRT was the only contributor to these cancer-
related outcomes, but such data might signal a possible therapeutic
gain of sterilizing as much known disease as possible at the time
of SBRT. Information on the durability of SBRT response would
strengthen this claim. As of this writing, such data is not sufficiently
mature. A phase I clinical trial testing SBRT and carboplatin –
gemcitabine combination that incorporates such information is
underway by our research team.
Stereotactic body radiosurgery was well tolerated in this study
despite a heavily pretreated group of patients. Any grade hema-
tological (8%) and grade 3 or 4 gastrointestinal (12%) toxicities
observed in our study compare favorably to hematological (19%
neutropenia, 9% anemia) and gastrointestinal (11%) of intensity-
modulated radiation therapy in the abdomen and pelvis (Brixey
et al., 2002; Mundt et al., 2003).
Strengths of our study include a contemporary study popu-
lation drawn among women with common metastatic gyneco-
logic cancers. SBRT was performed by a specialized radiation
therapy team led by experienced radiation oncologist and gyne-
cologic oncologists. Weaknesses include insufficient stratification
for gynecologic cancer type, which hampers our appraisal of clin-
ical benefit and progression-free survival. Moreover, the study
did not control for prior therapies and considerable variabil-
ity is identified in the study population. The study also could
be strengthened by longer-term follow-up for the sequelae of
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treatment, durability of SBRT target response, and cancer-related
outcome.
Our results indicate that SBRT safely delivers effective ablative
radiation dose to metastatic sites of gynecologic cancer. The ther-
apy can be administered with minimal toxicity even in a group of
heavily pretreated patients. While highly effective at treating tar-
geted lesions, many of these patients develop progressive disease.
An improved understanding of the safety and efficacy of SBRT
in conjunction with cytotoxic chemotherapy is of interest and is
currently under investigation.
PANEL: RESEARCH IN CONTEXT
Systematic review
Our manuscript reports the first phase II clinical trial of robotic
SBRT conducted in women with metastatic gynecological cancers.
We searched PubMed with the terms “radiosurgery,” “gynecologic
cancer,” and “clinical trial” for publications between January 1,
1999, and June 1, 2012. We broadened our publication search to
include radiosurgery conducted for the treatment of gynecologic
tumors. Single institution cohort studies of radiosurgery for gyne-
cological cancers were culled to put this research in context (Kunos
et al., 2008, 2009, 2012a; Choi et al., 2009; Deodato et al., 2011;
Higginson et al., 2011). The radiation dose delivery and schedule
vary considerably among these single institution cohort studies,
obscuring the totality of evidence for gynecologic cancer disease
control.
Interpretation
Our first-ever phase II clinical trial establishes clinical benefit of a
standardized (8 Gy× 3 consecutive day) robotic SBRT treatment
among 50 women with metastatic gynecological cancers. Based
on these findings, clinicians may consider SBRT a new treatment
option in this disease setting. Clinical trials incorporating SBRT
and co-administered chemotherapy are underway.
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